Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
17 yrs patint administered dose of kinrix; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of inappropriate age at vaccine administration in a 17-year-old patient who received DTPa-IPV (Kinrix) for prophylaxis. On 10-MAR-2025, the patient received Kinrix. On 10-MAR-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 17 yrs patint administered dose of kinrix). The outcome of the inappropriate age at vaccine administration was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-MAR-2025 The patient was administered dose of Kinrix at not recommended age due to their facility not having supply of an appropriate vaccine for polio for the patient's age group which led inappropriate age at vaccine administration. The reporter confirmed the patient has not reported any medical concerns or symptoms after been administered the Kinrix. The reporter consented for follow up.